VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was recently featured in an Applied Clinical Trials article titled, “Pushing Late-Stage Treatments Forward in the Clinic.” In the article, VistaGen’s CEO Shawn Singh discussed the company’s ongoing efforts to treat and help manage the anxiety symptoms provoked by COVID-19 and other triggers, anxiety-related disorders initially in subjects suffering from Social Anxiety Disorder (“SAD”), as well as the FDA’s consensus on the design of the company’s pivotal Phase III study of PH94B. The piece quotes Singh, who states, “Now more than ever, patients around the world need new medications that go beyond the standard of care for anxiety, depression and suicidal ideation. For patients who have a debilitating mental health condition, our goal with PH94B for SAD, as well as for several other anxiety disorders, is to develop and offer an innovative, life-changing treatment that goes beyond the current standard of care and allows patients to manage their anxiety to the point where they are able to live their lives as the ideal version of themselves—a crucial driver for everything we do.”
To view the full article, visit https://ibn.fm/Ym21x
About VistaGen Therapeutics
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
